|
½ÉÇ÷°üÁúȯÀº ¼¼°èÀûÀÎ ¹®Á¦ÀÔ´Ï´Ù. ¼±Áø±¹¿¡¼ ½ÉÇ÷°üÁúȯÀÇ Áõ°¡´Â ¿îµ¿ºÎÁ·, ºñ¸¸, Èí¿¬ µîÀÇ À§ÇèÀÎÀÚ, °Ç°¿¡ ÇØ·Î¿î ¶óÀÌÇÁ½ºÅ¸ÀÏ, ½ÉÀ庴ÀÇ À§ÇèÀ» Áõ°¡½ÃŰ´Â ´ç´¢º´°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ½ÉÇ÷°üÁúȯ Ä¡·á¾à µ¿Çâ, ´ëÇü Á¦¾àȸ»çÀÇ ½Å¾à°³¹ß µ¿Çâ, 2012³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.
4. ÄÝ·¹½ºÅ׷Ѱú Æ®¸®±Û¸®¼¼¶óÀ̵å(Áß¼ºÁö¹æ, Triglycerides)
- ÄÝ·¹½ºÅ×·Ñ °ü¸® ¾àÁ¦ ½ÃÀå
- ½ºÅ¸Æ¾
- ±âŸ Ç×°íÁöÇ÷Áõ ¾àÁ¦
- ÃÖ±ÙÀÇ Àΰ¡¿Í °³¹ßÁßÀÎ ¾àÁ¦
5. °íÇ÷¾Ð
- °íÇ÷¾Ð ¾àÁ¦ ½ÃÀå
- ¾ÈÁö¿ÀÅÙ½Å-II ¼ö¿ëü Â÷´ÜÁ¦(Angiotensin-II Receptor Blockers)
- µðÈ÷µå·ÎÇǸ®µò°è Ä®½·Ã¤³Î Â÷´ÜÁ¦(Dihydropyridine Calcium Channel Blockers)
- ACE ¾ïÁ¦Á¦
- º£Å¸Â÷´ÜÁ¦
- ¾ËÆÄ ¾Æµå·¹³¯¸° ¼ö¿ëü ±æÇ×Á¦(Alpha Adreno-Receptor Antagonists)
- º´¿ëÁ¦Ç°
- ÃÖ±ÙÀÇ Àΰ¡¿Í °³¹ßÁßÀÎ ¾àÁ¦
6. °üµ¿¸ÆÁúȯ
- Çù½ÉÁõ
- ÃÖ±ÙÀÇ Àΰ¡¿Í °³¹ßÁßÀÎ ¾àÁ¦
7. ½É¹æ¼¼µ¿
- ÇöÀçÀÇ Ä¡·á¹ý
- °³¹ßÁßÀÎ ¾àÁ¦
9. Ç÷ÀüÁõ
- Ç÷ÀüÁõ Ä¡·á¾à ½ÃÀå
- ÃÖ±ÙÀÇ Àΰ¡¿Í °³¹ßÁßÀÎ ¾àÁ¦
ksm
|